I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Zellweger Spectrum Disorders NGS Panel
Zellweger spectrum disorders (ZSD) consist of Zellweger syndrome (cerebro-hepato-renal syndrome; most severe phenotype), neonatal adrenoleukodystrophy (NALD; intermediate phenotype) and infantile Refsum disease (IRD; mildest phenotype). ZSD are associated with abnormal brain development, liver dysfunction, skeletal and renal defects. Zellweger syndrome patients are severely affected from birth; they are dysmorphic, hypotonic, developmentally delayed and have failure to thrive. In contrast, IRD patients have visual and auditory sensory deficits, with or without developmental delay, as their main features. ZSD patients have elevated plasma very long chain fatty, deficient red blood cell plasmalogens, and elevated plasma and/or urine pipecolic acid. Some patients have equivocal blood metabolite levels and may need further metabolic testing in cultured fibroblasts or DNA testing to make a final diagnosis. Copies of the patient's biochemical analysis are extremely helpful in result interpretation.
Autosomal Recessive; Autosomal Dominant
Missense mutations may be associated with milder clinical and biochemical phenotypes; however, this can be specific to certain mutations in certain genes.
Next Generation Sequencing (NGS) of the coding regions and intron-exon boundaries of the listed genes; Deletion/Duplication: Dosage analysis by normalization of NGS read depth for the listed genes (except DNM1L); Sanger sequencing for potential fill in / confirmation
This test is also available as part of one or more NGS panels for peroxisomal disorders.
Identification of causative mutations in known or highly suspicious cases of ZSD based on clinical presentation and the blood biomarker profile; rule-out ZSD in the presence of equivocal clinical presentation and/or biomarker profile; targeted carrier testing of relatives of proband; predictive prenatal testing when familial mutations are known.
Sequencing: The sequencing panel will detect at least one mutation in 99% of patients. Two causative mutations in a single gene should be identified in at least 98% of patients. There have been individual case reports of deletions/duplications in multiple PEX genes, but no published case series.
> 99% for inherited single nucleotide and small insertion/deletion variants for the nucleotides evaluated; >99% for multi-exon deletions and >98% for single exon deletions; >90% for multi-exon duplications and >75% for single exon duplications. Lower limit of detection for single nucleotide variants: 25% allele frequency (>99% sensitivity).
We prefer whole blood for all tests.
Turn Around Time
Approximately 4 weeks
Fee and CPT Codes
NGS Panel: $3211 for routine testing
CPT Code: 81479 x 13
We request that copies of the patient's biochemical analysis be submitted with the sample.
Digenic inheritance (disease caused by mutations in 2 different PEX genes) has not been reported, but remains a theoretical possibility.
INFORMED CONSENT from the patient is required prior to ordering a genetic test. The DNA Diagnostic Lab's consent is located on the second page of the requisition form. There is also a patient brochure, "Things Every Patient Should Know Before Consenting to a Genetic Test", available for download.